Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivelin-CLO patches in oral lichen planus
2017-002193-40Phase 2Completed
- Sponsor
- AFYX Therapeutics
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Rivelin and clobetasol in oral lichen planus (OLP) (4 arms), sponsored by AFYX Therapeutics. Started Dec 2017; status: completed.
02
Drugs
Rivelinclobetasol
03
Conditions
oral lichen planus (OLP)
Beyond the preview
Go deeper on 2017-002193-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002193-40.